A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

This study is testing whether giving immunotherapy less often (less frequent dosing) is just as effective as standard dosing for people with certain advanced cancers — including stomach, liver, and lung cancer. Reducing frequency could lower costs and side effects without compromising results. **You may be eligible if...** - You have not yet received treatment for your advanced cancer and fall into one of these groups: - Stomach or esophageal cancer (PDL1 positive) starting platinum chemotherapy and nivolumab - Liver cancer (Child's A, hepatocellular carcinoma) starting atezolizumab and bevacizumab - Lung adenocarcinoma (PDL1 high, no EGFR/ALK mutations) starting pembrolizumab - You can provide informed consent **You may NOT be eligible if...** - You have already received systemic treatment for your advanced cancer - You have active autoimmune disease or serious organ problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.